Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Cedilla Therapeutics is raising $60,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Alexandra Glucksmann played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cedilla Therapeutics
For 60 years, sequence and structure has been the primary lens to understand protein function. Its now time to look beyond and leverage the orchestration of protein function within cells. The richness of the cellular context gives us a unique approach to target key cancer drivers that historically remained beyond the reach of drug discovery methods. Cedilla is developing novel small-molecule therapeutics directed to unrecognized allosteric binding sites, providing new ways to target key cancer drivers and treat life threatening diseases.

To learn more about Cedilla Therapeutics, visit http://www.cedillatx.com/

Contact:
Alexandra Glucksmann, President and Chief Executive Officer
617-281-5658
https://www.linkedin.com/in/alexandra-sandra-glucksmann-417a432/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved